Skip to main content
. 2021 Mar 17;11:643613. doi: 10.3389/fonc.2021.643613

Figure 1.

Figure 1

LncRNA POU3F3 maintains melanoma cell survival with DTIC treatment. (A) The lncRNA POU3F3 expression level was measured in DTIC-resistant melanoma cells and parental A375 and MV3 melanoma cells. GAPDH was used as the control. (B) The DTIC-resistant or parental A375 and MV3 cells were transfected with siRNA-NC/siRNA-lncRNA POU3F3 or Vector-NC/lncRNA POU3F3. The lncRNA POU3F3 expression levels were measured with qRT-PCR assays. (C,D) The transfected parental and DTIC-resistant A375 cells were treated with a series dose of DTIC (1–2,000 μg/ml) for 48 h, and cell viability was determined by MTT assays. IC50 was analyzed with the percentage of cell viability inhibition. (E) LncRNA POU3F3 overexpressing cells and control cells were treated with DTIC (25 μg/ml) for 3 days. The cell proliferation was detected with MTT assays. (F) In total, 1,000 transfected DTIC-resistant and parental A375 cells were cultured with DTIC (25 μg/ml) for 10 days. Cell colony number was compared among the groups. The data are presented as mean ± SD of three independent experiments, where *p < 0.01. LncRNA, long non-coding RNAs; DTIC, dacarbazine; siRNA, small interfering RNAs; qRT-PCR, quantitative real-time PCR.